NELMAS Study
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases (NELMAS). An international multi-centre, open, randomised, parallel-group phase II study comparing adjuvant treatment with 177Lu-DOTATATE to best supportive care in patients after complete surgical removal of neuroendocrine liver metastases.
CLICK HERE to read the study overview, full eligibility and exclusion criteria.
Referrals for this study will be through your specialist clinical team.
BackSOM Study
A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly (BackSOM)
Participants of this study are adults with GEP-NETs and/or acromegaly who were using the Ipsen lanreotide syringe and have transitioned in the last 6 months to the Pharmathen lanreotide syringe, having received at least two injections using the Pharmathen syringe.
CLICK HERE to read the study overview, full eligibility and exclusion criteria.
Referrals for this study will be through your specialist clinical team.
www.neuroendocrinecancer.org.uk
Made with FlippingBook interactive PDF creator